The stock of IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) hit a new 52-week high and has $3.34 target or 6.00% above today’s $3.15 share price. The 6 months bullish chart indicates low risk for the $93.65M company. The 1-year high was reported on Nov, 25 by Barchart.com. If the $3.34 price target is reached, the company will be worth $5.62M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 5.00% or $0.15 on November 25, hitting $3.15. About 1.14 million shares traded hands or 250.52% up from the average. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) has risen 44.23% since April 22, 2016 and is uptrending. It has outperformed by 38.82% the S&P500.
Analysts await IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) to report earnings on February, 24. They expect $-0.06 EPS, up 53.85% or $0.07 from last year’s $-0.13 per share. After $-0.07 actual EPS reported by IntelliPharmaCeutics Intl Inc (USA) for the previous quarter, Wall Street now forecasts -14.29% EPS growth.
According to Zacks Investment Research, “Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada.”
More news for IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) were recently published by: Schaeffersresearch.com, which released: “Buzz Stocks: Ericsson, Newell Brands Inc, and IntelliPharmaCeutics Intl Inc (USA)” on October 12, 2016. Benzinga.com‘s article titled: “The FDA’s Historic Caution On Abuse Deterrent Labeling” and published on November 25, 2016 is yet another important article.
IPCI Company Profile
Intellipharmaceutics International Inc., incorporated on October 22, 2009, is a pharmaceutical firm specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, the Company has developed several drug delivery systems and a pipeline of products and product candidates at various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. The Hypermatrix family of technologies includes IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle, Point of Divergence Drug Delivery System (nPODDDS) and Paradoxical OverDose Resistance Activating System (PODRAS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.